252 related articles for article (PubMed ID: 18341638)
21. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
[TBL] [Abstract][Full Text] [Related]
22. Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura.
Ren H; Zhao H; Wang T; Yang Y; Han Z; Liu B; Wu Z; Tao J; Zhou B; Zhang L; Yang R; Han ZC
Clin Immunol; 2006 Aug; 120(2):205-11. PubMed ID: 16774845
[TBL] [Abstract][Full Text] [Related]
23. Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients.
Bussel JB
Semin Oncol; 2000 Dec; 27(6 Suppl 12):91-8. PubMed ID: 11226007
[TBL] [Abstract][Full Text] [Related]
24. Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L.
Fan Y; Ge Y; Zhu H; Wang Y; Yang B; Zhuang Y; Ma H; Zhang X
Tissue Antigens; 2004 Sep; 64(3):257-63. PubMed ID: 15304006
[TBL] [Abstract][Full Text] [Related]
25. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
26. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.
Wang J; Wiley JM; Luddy R; Greenberg J; Feuerstein MA; Bussel JB
J Pediatr; 2005 Feb; 146(2):217-21. PubMed ID: 15689912
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of T cell activation by immobilized hu5C8 (anti-CD40L) monoclonal antibody.
Arpinati M; Chirumbolo G; Rondelli D
Eur J Haematol; 2008 Apr; 80(4):322-30. PubMed ID: 18081708
[TBL] [Abstract][Full Text] [Related]
29. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection.
Pockros PJ; Duchini A; McMillan R; Nyberg LM; McHutchison J; Viernes E
Am J Gastroenterol; 2002 Aug; 97(8):2040-5. PubMed ID: 12190174
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
Ewenstein BM; Hoots WK; Lusher JM; DiMichele D; White GC; Adelman B; Nadeau K
Haematologica; 2000 Oct; 85(10 Suppl):35-9. PubMed ID: 11187868
[TBL] [Abstract][Full Text] [Related]
31. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
Zaja F; Battista ML; Pirrotta MT; Palmieri S; Montagna M; Vianelli N; Marin L; Cavallin M; Bocchia M; Defina M; Ippoliti M; Ferrara F; Patriarca F; Avanzini MA; Regazzi M; Baccarani M; Isola M; Soldano F; Fanin R
Haematologica; 2008 Jun; 93(6):930-3. PubMed ID: 18403395
[TBL] [Abstract][Full Text] [Related]
32. Current options for the treatment of idiopathic thrombocytopenic purpura.
Arnold DM; Kelton JG
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura.
Ramadan KM; El-Agnaf M
Clin Lab Haematol; 2005 Aug; 27(4):267-9. PubMed ID: 16048495
[TBL] [Abstract][Full Text] [Related]
34. Novel approaches to refractory immune thrombocytopenic purpura.
Bussel JB
Blood Rev; 2002 Mar; 16(1):31-6. PubMed ID: 11913991
[TBL] [Abstract][Full Text] [Related]
35. The effect of platelet autoantibodies on the course of the disease and clinical response of patients with idiopathic thrombocytopenic purpura.
Sikorska A; Konopka L; Maślanka K
Int J Lab Hematol; 2008 Feb; 30(1):58-64. PubMed ID: 18190469
[TBL] [Abstract][Full Text] [Related]
36. IDEC-131. IDEC/Eisai.
Dumont FJ
Curr Opin Investig Drugs; 2002 May; 3(5):725-34. PubMed ID: 12090546
[TBL] [Abstract][Full Text] [Related]
37. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.
Medeot M; Zaja F; Vianelli N; Battista M; Baccarani M; Patriarca F; Soldano F; Isola M; De Luca S; Fanin R
Eur J Haematol; 2008 Sep; 81(3):165-9. PubMed ID: 18510702
[TBL] [Abstract][Full Text] [Related]
38. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
39. Abnormality of regulatory T-cells in remission and non-remission idiopathic thrombocytopaenic purpura patients.
Teke HÜ; Gündüz E; Akay OM; Gülbas Z
Platelets; 2013; 24(8):625-31. PubMed ID: 23215839
[TBL] [Abstract][Full Text] [Related]
40. [Refractory idiopathic thrombocytopenic purpura].
Iki S; Urabe A
Nihon Rinsho; 2003 Apr; 61(4):609-14. PubMed ID: 12718084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
